WHO ICTRP trial
The role of 25-hydroxyvitamin D in insulin resistance and inflammation in…
ACTRN12609000246280 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12609000246280 |
|---|---|
| Public title | The role of 25-hydroxyvitamin D in insulin resistance and inflammation in patients with Chronic Kidney Disease: A randomised controlled trial. |
| Scientific title | The role of 25-hydroxyvitamin D in insulin resistance and inflammation in patients with Chronic Kidney Disease: A randomised controlled trial. |
| Primary sponsor | A/Prof Nicole Isbel |
| Secondary sponsors | Princess Alexandra Hospital |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not Applicable |
| Countries | Australia |
| Conditions | Chronic Kidney Disease Stage 3;Vitamin D deficiency; Chronic Kidney Disease Stage 3 Vitamin D deficiency;Metabolic and Endocrine - Metabolic disorders;Inflammatory and Immune System - Other inflammatory or immune system disorders |
| Interventions | Cholecalciferol (vitamin D3) oral tablets (1000IU/25micrograms), 2 tablets/day for a total of 6 months. It was not felt to be ethical to randomise patients who were frankly vitamin D deficient. However, useful data can be obtained using the… |
| Registration date | Dec 5, 2009 |
| Target size | 51 |
| Secondary IDs | Nil. |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: